株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CTLA4(細胞傷害性Tリンパ球関連タンパク質4)阻害剤の世界市場:2019年~2023年

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by Type and Geography - Global Forecast and Analysis 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 910217
出版日 ページ情報 英文 116 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
CTLA4(細胞傷害性Tリンパ球関連タンパク質4)阻害剤の世界市場:2019年~2023年 CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by Type and Geography - Global Forecast and Analysis 2019-2023
出版日: 2019年09月03日 ページ情報: 英文 116 Pages
概要

世界ののCTLA4(細胞傷害性Tリンパ球-リンパ球関連タンパク質4)阻害剤市場は、CTLA4阻害剤の高い標的親和性と特異性、併用療法人気の高まり、戦略的提携などが成長促進要因となり、予測期間中に9%以上のCAGRで拡大する見込みです。ただし、承認された治療法の欠如、代替品の入手可能性、厳しい規制などの要因により、予測期間中のCTLA4阻害剤産業の成長が妨げられる可能性があります。

当レポートでは、世界のCTLA4(細胞傷害性Tリンパ球関連タンパク質4)阻害剤市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別
  • 比較:タイプ別市場規模および予測(2018年~2023年)
  • 単剤療法
  • 併用療法
  • 市場機会:タイプ別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 研究適応の拡大
  • 特別薬の指定
  • 癌に関する意識の高まり

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • 小野薬品工業

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31971

About this market

Technavio's CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis considers sales from both monotherapy and combination therapy . Our analysis also considers the sales of CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) inhibitors in Asia, Europe, North America, and ROW. In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low side effects due and better tolerability will play a significant role in the monotherapy segment to maintain its market position. Also, our global CTLA4 inhibitors market report looks at factors such as high target affinity and specificity of CTLA4 inhibitors, growing popularity of combination therapy, and strategic alliances. However, lack of approved therapies, availability of substitutes, and stringent regulations may hamper the growth of the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors industry over the forecast period.

Overview

High target affinity and specificity of CTLA4 inhibitors

CTLA4 inhibitors function by boosting the immune system and reducing the side effects. CTLA-4 is a protein found on the surface of T-cells which suppress the growth of cancer cells by activating the immune system. These drugs work directly on the target, and their efficacy is higher than that of other conventional treatments such as chemotherapy. Though the CTLA4 inhibitors are new to the oncology treatment landscape, increasing R&D efforts by market vendors are supporting the growth of CTLA4 inhibitors market This will lead to the expansion of the global CTLA4 inhibitors market at a CAGR of over 9% during the forecast period.

Increasing awareness about cancer

The awareness programs conducted by various organizations provide an opportunity to raise awareness about lung cancer screening and treatment options, including CTLA4 inhibitors. For instance, Cancer Breakthroughs 2020 an initiative taken by the US government for the development of research on vaccine-based immunotherapies for cancer. This project aimed at making therapies available to more patients while detecting the disease at an early stage. Such awareness programs are also raising awareness about the treatment of various cancer types by using CTLA4 inhibitors. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global CTLA4 inhibitors market is highly concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading CTLA4 inhibitors manufacturers, that include AstraZeneca Plc, Bristol-Myers Squibb Co., Ono Pharmaceutical Co. Ltd.

Also, the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Monotherapy - Market size and forecast 2018-2023
  • Combination therapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Expansion of research indications
  • Special drug designations
  • Increasing awareness about cancer

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Ono Pharmaceutical Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: AstraZeneca Plc - Vendor overview
  • Exhibit 45: AstraZeneca Plc - Business segments
  • Exhibit 46: AstraZeneca Plc - Organizational developments
  • Exhibit 47: AstraZeneca Plc - Geographic focus
  • Exhibit 48: AstraZeneca Plc - Key offerings
  • Exhibit 49: AstraZeneca Plc - Key customers
  • Exhibit 50: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 51: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 52: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 53: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 54: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 55: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 56: Ono Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 57: Ono Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 58: Ono Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 59: Ono Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 60: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 61: Ono Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 62: Validation techniques employed for market sizing
  • Exhibit 63: Definition of market positioning of vendors
Back to Top